Invitation to comment on the commercial
supply of cat vaccines containing a genetically modified component (DIR 220)

The Gene Technology Regulator is assessing an application from Intervet Australia Pty Ltd for the commercial supply of multivalent cat vaccines containing a genetically modified component to protect cats against Feline leukemia virus infection.

The vaccine must also be registered by the Australian Pesticides and Veterinary Medicines Authority (APVMA) before it is approved for use in Australia and would be prescription only.

The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application and welcomes written submissions on any risks to human or animal health and the environment posed by the import, transport, storage and disposal of this vaccine and is seeking comment on the assessment prior to making a decision on whether to issue the licence.

The consultation RARMP and related information can be obtained via https://consultations.health.gov.au/ogtr/dir-220-consultation, or from the contacts below. Submissions should reference DIR 220 and be received by 2 June 2026.

Office of the Gene Technology Regulator
MDP 54 GPO Box 9848 CANBERRA ACT 2601

Telephone: 1800 181 030 Website: www.ogtr.gov.au

E-mail: ogtr@health.gov.au

Invitation to comment on the commercial supply of cat vaccines containing a genetically modified component (DIR 220)

Invitation to comment on the commercial
supply of cat vaccines containing a genetically modified component (DIR 220)